Transkaryotic Therapies, Inc.

Jul 27, 05
	NEW STORY
10:36 ET	TKT Stockholders Approve Acquisition by Shire
Jul 14, 05
17:22 ET	TKT Confirms That Board of Directors Unanimously Recommends That Stockholders Approve Shire Transaction
Jul 12, 05
08:02 ET	TKT Issues Open Letter to Stockholders
Jun 27, 05
13:14 ET	TKT to Hold Special Meeting of Stockholders on July 27, 2005
Jun 20, 05
08:04 ET	TKT Reports Positive Top-Line Results of Hunter Syndrome Pivotal Trial
Jun 13, 05
08:41 ET	TKT Announces Expiration of Both Hart-Scott-Rodino Waiting Period and SEC Review Period of Preliminary Proxy Statement
May 05, 05
08:00 ET	TKT Announces First Quarter 2005 Results
Apr 27, 05
18:23 ET	TKT Assessing Impact of Fire at Manufacturing Facility
16:31 ET	TKT to Report First Quarter 2005 Financial Results on May 5, 2005
Apr 21, 05
09:50 ET	TKT Announces Agreement to be Acquired by Shire for $1.6 Billion
Apr 20, 05
09:43 ET	TKT Achieves GA-GCB Clinical Milestone
Mar 29, 05
14:23 ET	TKT Announces Appointment of Eric Pauwels as Senior Vice President, Global Commercial Operations
Mar 28, 05
16:04 ET	New Website Offers Comprehensive Information on Hunter Syndrome
Mar 24, 05
09:30 ET	TKT to Present at Two Upcoming Healthcare Conferences
Mar 09, 05
14:29 ET	TKT to Present at SG Cowen Securities' 25th Annual Healthcare Conference
14:21 ET	TKT to Present at SG Cowen Securities' 25th Annual HealthCare Conference
Feb 25, 05
09:30 ET	National MPS Society Opens NASDAQ Stock Market
Feb 23, 05
08:05 ET	Strong Year of Execution Produces Solid 2004 Financial Performance
Feb 15, 05
09:31 ET	Tamara L. Joseph Named General Counsel of TKT
Feb 10, 05
09:17 ET	TKT to Report Fourth Quarter and Year-End 2004 Financial Results on February 23, 2005
Feb 04, 05
09:15 ET	TKT Appoints Theresa Heggie as General Manager, Europe
Jan 24, 05
15:59 ET	Genzyme Sues to Halt TKT Gaucher Trial
Jan 11, 05
16:01 ET	TKT Provides Update on Product Pipeline at JPMorgan Healthcare Conference
Jan 04, 05
10:02 ET	TKT to Present at JPMorgan's Annual HealthCare Conference
Dec 09, 04
11:23 ET	TKT to Present at Wachovia Biotechnology Conference
Nov 12, 04
09:15 ET	TKT Announces Executive Promotions
Nov 09, 04
08:35 ET	TKT to Present At SG Cowen's Fifth Annual Global Health Care Conference
08:31 ET	TKT Reports Third Quarter 2004 Financial Results
Oct 29, 04
15:58 ET	TKT To Report Third Quarter Financial Results On November 9, 2004
Oct 28, 04
17:01 ET	TKT's Research Findings on Intrathecal Delivery of I2S Presented at ASHG
Oct 22, 04
08:06 ET	TKT Completes Acquisition of Minority Interest in TKT Europe-5S AB
Oct 21, 04
07:16 ET	TKT Prevails Over Kirin-Amgen in House of Lords Dynepo Litigation Amgen Patent Found Invalid
Oct 15, 04
19:34 ET	TKT to Appeal Dynepo Ruling to Federal Circuit
Sep 28, 04
16:05 ET	TKT's I2S for Hunter Syndrome Receives Office of Orphan Products Grant
Sep 22, 04
09:05 ET	TKT Announces Appointments in Business Development and Intellectual Property
Sep 20, 04
14:03 ET	TKT to Present Research on Intrathecal Delivery of I2S For Hunter Syndrome at ASHG
09:28 ET	TKT to Present at UBS Global Life Sciences Conference
Sep 13, 04
08:39 ET	TKT Gains Early Access to Dynepo(TM) Oncology Data
Sep 02, 04
11:03 ET	TKT to Present at Thomas Weisel's Healthcare Tailwinds Conference
Aug 31, 04
20:07 ET	TKT to Defend Vigorously U.S. Patent Litigation Brought by Serono
Aug 03, 04
08:30 ET	TKT Reports Second Quarter 2004 Financial Results
02:00 ET	TKT Announces Manufacturing Agreement for Dynepo
Jul 27, 04
10:32 ET	TKT to Report Second Quarter Financial Results on August 3, 2004
Jul 26, 04
10:27 ET	TKT Completes Enrollment in Clinical Trial for Gaucher Disease
Jul 23, 04
10:44 ET	TKT to Present at Two Upcoming Conferences
Jul 22, 04
16:58 ET	TKT Receives 'Wells Notice' from SEC
Jul 15, 04
16:01 ET	TKT Receives Fast Track Designation For Iduronate-2-Sulfatase for Hunter Syndrome
Jun 03, 04
14:07 ET	TKT to Present at Pacific Growth Equities Life Sciences Growth Conference
Jun 02, 04
08:58 ET	TKT Announces Appointment of Dr. Marcio Voloch
May 13, 04
09:49 ET	TKT to Present at Banc of America's 2004 Health Care Conference
May 10, 04
11:38 ET	Massachusetts Court Dismisses TKT Derivative Lawsuit
Apr 30, 04
10:11 ET	TKT to Present at Deutsche Bank Securities 29th Annual Healthcare Conference
Apr 28, 04
18:07 ET	TKT Announces $90 Million Public Offering of 1.25% Senior Convertible Notes Due 2011
Apr 27, 04
16:23 ET	TKT Announces Proposed Offering Of Senior Convertible Notes Due 2011
08:52 ET	Wayne P. Yetter Named Chairman of TKT's Board of Directors
08:41 ET	TKT Announces First Quarter 2004 Results
Apr 26, 04
09:12 ET	TKT Begins Clinical Trial for Gaucher Disease
Apr 21, 04
14:56 ET	TKT to Report First Quarter Financial Results on April 27, 2004
Mar 26, 04
11:30 ET	TKT Regains European Rights to Dynepo
Mar 11, 04
08:33 ET	TKT Announces Fourth Quarter and Year End 2003 Results
Mar 05, 04
16:30 ET	TKT to Report Fourth Quarter and Year-End 2003 Financial Results on March 11, 2004
09:02 ET	TKT Completes Patient Enrollment in Pivotal Hunter Syndrome Clinical Trial
Feb 25, 04
09:36 ET	TKT to Present at Two Upcoming Healthcare Conferences
Feb 23, 04
08:32 ET	TKT to Complete Enrollment in Pivotal Hunter Syndrome Trial in Early March
Feb 18, 04
10:24 ET	TKT to Participate at BIO CEO & Investor Conference
Feb 09, 04
08:39 ET	TKT Receives Canadian Approval of Replagal(TM) to Treat Fabry Disease
Jan 29, 04
13:15 ET	Paul McCabe Joins TKT as Country Manager, Canada
Jan 12, 04
12:08 ET	TKT to End Efforts to Seek U.S. Approval of Replagal
08:58 ET	TKT Names Dr. Paul M. Martha, Vice President, Clinical Affairs
Jan 06, 04
13:56 ET	TKT Announces Webcast of Presentation at Upcoming JPMorgan Healthcare Conference
Dec 30, 03
08:34 ET	TKT and Orphan Australia Enter Into Marketing and Distribution Agreement For Replagal(TM)
Dec 04, 03
09:13 ET	TKT Announces Webcast of Presentation at Upcoming Harris Nesbitt Gerard Healthcare Conference
Dec 01, 03
14:30 ET	TKT Announces Changes to its Board of Directors
Nov 06, 03
21:30 ET	Long-Term Phase I/II Data from TKT's I2S Trial Presented at ASHG Annual Meeting
Oct 29, 03
08:34 ET	TKT Reports Record Replagal Sales
Oct 22, 03
09:42 ET	TKT Announces Date of Third Quarter 2003 Financial Results and Investor Meeting at ASHG
Oct 10, 03
10:57 ET	European Patent Office Affirms Revocation of Serono Gene Activation Patent
Oct 09, 03
12:04 ET	TKT Announces Favorable Ruling in Replagal Patent Litigation Federal Circuit Affirms District Court Decision of Non-Infringement
Oct 08, 03
16:02 ET	Genzyme and TKT Form Collaboration to Develop and Commercialize I2S for Hunter Syndrome in Japan
Sep 24, 03
10:31 ET	Long-term Data From TKT's Phase I/II Hunter Syndrome Trial to be Presented at ASHG Meeting
Sep 22, 03
13:16 ET	TKT Promotes David Pendergast to Chief Operating Officer
Sep 19, 03
08:55 ET	TKT Initiates Pivotal Trial for Hunter Syndrome
Sep 16, 03
09:03 ET	TKT Announces Webcast of Presentation at Upcoming UBS Global Life Sciences Conference
Sep 04, 03
08:43 ET	TKT's Long-Term Hunter Syndrome Phase I/II Data Show Continued Improvement in Patients
Aug 11, 03
09:01 ET	TKT Retakes Factor VIII Gene Therapy Rights from Wyeth TKT Intends to Relicense Program
Jul 29, 03
08:09 ET	TKT Reports Second Quarter 2003 Financial Results
Jul 23, 03
09:34 ET	European Commission Approves TKT's Cambridge, Massachusetts Manufacturing Facility to Produce Replagal for Commercial Sale
Jul 22, 03
10:34 ET	TKT to Announce Second Quarter 2003 Financial Results on July 29, 2003
May 16, 03
08:40 ET	Research Program Funded by TKT Highlighted in Cell
May 14, 03
16:35 ET	TKT Receives Formal Order of Investigation by SEC
08:41 ET	TKT Announces Management Changes in Research Department
May 05, 03
08:10 ET	Data from European Fabry Outcomes Survey (FOS) Confirms Beneficial Effects of Replagal
08:06 ET	TKT Appoints Gregory D. Perry, Vice President, Finance and Chief Financial Officer
08:05 ET	TKT Announces First Quarter 2003 Financial Results
May 01, 03
12:22 ET	TKT to Announce First Quarter 2003 Financial Results on May 5, 2003
Apr 29, 03
09:23 ET	TKT Announces Webcast of Presentation at Upcoming Deutsche Bank Health Care Conference
Apr 17, 03
16:05 ET	TKT Announces Purported Derivative Lawsuit
Apr 04, 03
08:31 ET	TKT Announces Resignation of Daniel E. Geffken as Chief Financial Officer
Mar 31, 03
08:34 ET	TKT Announces Fourth Quarter and Year-End 2002 Financial Results
Mar 28, 03
17:20 ET	TKT to Announce Fourth Quarter and Year-End 2002 Financial Results on March 31, 2003
Mar 26, 03
09:22 ET	TKT Announces Issuance of Two Gene Therapy Patents
Mar 19, 03
12:14 ET	TKT Provides Update on Participation at Upcoming Health Care Conferences
12:13 ET	TKT Announces Reduction in Workforce as Company Focuses on Core Business Areas
Mar 13, 03
10:27 ET	TKT Announces Webcast of Presentation at Upcoming SG Cowen Health Care Conference
Feb 27, 03
09:47 ET	TKT Announces Webcast of Presentation at Upcoming Lehman Brothers Global Health Care Conference
Feb 25, 03
09:30 ET	Issuance of U.S. Patent Expands TKT Intellectual Property Position in MPS Disorders
Feb 14, 03
15:59 ET	House of Lords to Hear Dynepo(TM) Appeal
Feb 11, 03
17:13 ET	TKT Announces Appointment of Michael J. Astrue as Chief Executive Officer
Feb 03, 03
16:01 ET	TKT Announces Alleged Patent Infringement Suit by Serono Relating to Replagal(TM)
Jan 27, 03
11:00 ET	TKT Announces Purported Class Action Lawsuit
Jan 14, 03
19:04 ET	TKT Will Press for Approval Following FDA Advisory Committee Review of Replagal(TM)
Jan 13, 03
07:50 ET	TKT Announces Briefing Documents for FDA Advisory Committee Meeting Available Today
Jan 07, 03
08:42 ET	TKT Encouraged by U.S. Court of Appeals Decision on Patent Litigation Against Amgen
Nov 27, 02
07:56 ET	TKT Reports Preliminary Results From New Clinical Study of Replagal(TM)
Oct 30, 02
16:08 ET	TKT Announces European Commission Expands Replagal(TM) Label to Include Females
16:06 ET	TKT Reports Third Quarter 2002 Financial Results
Oct 28, 02
10:40 ET	FDA Advisory Committee to Consider TKT's Replagal January 14, 2003
Oct 23, 02
16:12 ET	TKT to Announce Third Quarter 2002 Financial Results on October 30, 2002
Oct 16, 02
16:31 ET	New Treatment Holds Promise of Helping Children Afflicted with Hunter Syndrome
16:29 ET	TKT Reports Results of Phase I/II Clinical Trial of Enzyme Replacement Therapy for Hunter Syndrome
Oct 02, 02
16:05 ET	TKT Provides Regulatory and Commercial Updates on Fabry Disease Program
Sep 20, 02
12:56 ET	TKT Announces FDA Postpones September 26 and 27, 2002 Advisory Committee Meetings
Sep 06, 02
09:18 ET	TKT Announces Expansion of Management Team
Jul 31, 02
16:16 ET	TKT Reports Second Quarter 2002 Financial Results
09:47 ET	TKT Announces Victory Over Amgen in Dynepo(TM) U.K. Patent Litigation
Jul 17, 02
10:41 ET	TKT to Announce Second Quarter 2002 Financial Results on July 31, 2002
Jul 08, 02
13:39 ET	TKT Announces Meeting of FDA Advisory Committee to Review Replagal(TM) BLA for Fabry Disease
Jun 27, 02
12:21 ET	TKT's Richard Selden Wins Ernst & Young New England Entrepreneur of the Year Award
Jun 12, 02
09:14 ET	TKT Announces Positive Preliminary Findings in Development of Iduronate-2- Sulfatase for Hunter Syndrome
Jun 10, 02
08:31 ET	TKT Broadens Intellectual Property Estate Through Two Licensing Agreements
May 02, 02
16:18 ET	TKT Reports First Quarter 2002 Financial Results
Apr 19, 02
09:04 ET	TKT Announces Date of First Quarter 2002 Financial Results and Conference Call
Apr 09, 02
09:53 ET	TKT Announces Senior Appointments in Manufacturing and Product Development
Mar 26, 02
09:51 ET	TKT Announces Approval of Dynepo(TM) in the European Union
Mar 19, 02
10:06 ET	TKT Reaches Settlement in Gene Therapy Patent Interferences
Feb 11, 02
16:16 ET	TKT Announces Fourth Quarter and Year-End 2001 Financial Results
Jan 28, 02
09:43 ET	TKT Announces Date of Fourth Quarter 2001 Financial Results and Conference Call
Jan 17, 02
10:21 ET	Shelter, Inc. Elects Daniel E. Geffken To Board Of Directors
Jan 09, 02
13:02 ET	TKT Announces New Additions To Management Team
Jan 07, 02
09:46 ET	TKT's Replagal(TM) Receives Marketing Approval in Israel, Switzerland, and Czech Republic
Jan 03, 02
08:47 ET	TKT Granted Orphan Drug Status for Hunter Syndrome Treatment in Both Europe And The United States
Dec 20, 01
08:53 ET	TKT Announces $42 Million Public Offering of Common Stock
Dec 18, 01
14:35 ET	TKT Announces Exercise of Overallotment Option
Dec 17, 01
08:50 ET	TKT Announces Victory in Genzyme Patent Litigation - No Infringement; Trial Cancelled -
Dec 12, 01
19:26 ET	TKT Announces Completion of $109 Million Public Offering of Common Stock
09:02 ET	TKT and Aventis Receive Recommendation for Marketing Approval of Dynepo(TM) in European Union
Nov 29, 01
07:34 ET	TKT Announces Favorable Outcome in Markman Hearing in Replagal(TM) Patent Litigation
Nov 13, 01
09:49 ET	TKT Names John T. Flaherty Vice President, Medical Affairs
Oct 29, 01
16:15 ET	TKT Announces Third Quarter 2001 Financial Results
Oct 23, 01
08:32 ET	TKT Awarded U.S. Patent Relating to Protein Production and Delivery For Gene Therapy
Oct 19, 01
09:11 ET	TKT's Replagal(TM) Enzyme Replacement Therapy for Fabry Disease Granted Marketing Approval in New Zealand and Iceland
Oct 16, 01
13:15 ET	TKT Reports Long-Term Clinical Results of Replagal(TM) Enzyme Replacement Therapy For Fabry Disease
Oct 15, 01
11:29 ET	TKT Announces Date Of Third Quarter 2001 Financial Results and Conference Call
Sep 27, 01
09:36 ET	TKT Names Top Litigator as Vice President and Chief Intellectual Property Counsel
Sep 25, 01
10:22 ET	Additional Results of TKT's Replagal(TM) Enzyme Replacement Therapy Published in Circulation
Sep 06, 01
11:01 ET	TKT Reports Results from First Ever Study of Females with Fabry Disease
Aug 16, 01
08:58 ET	TKT's Replagal(TM) Enzyme Replacement Therapy for Fabry Disease Approved in Norway
Aug 14, 01
09:14 ET	TKT Awarded Broad Patent Relating to Production and Delivery of Proteins
Aug 08, 01
08:38 ET	TKT Announces the Appointment of Helen Critchley to Vice President, International Regulatory Affairs
Aug 03, 01
08:47 ET	New Treatment Available for Fabry Disease In Europe
Jul 31, 01
16:16 ET	TKT Announces Second Quarter 2001 Financial Results
Jul 20, 01
19:33 ET	TKT Announces Date of Second Quarter 2001 Financial Results and Conference Call
Jul 10, 01
08:32 ET	TKT Announces Issuance of U.S. Patent Relating to Sanfilippo Syndrome Type B (MPS IIIB)
Jul 02, 01
08:31 ET	TKT Completes $100 Million Public Offering of Common Stock
Jun 25, 01
18:19 ET	TKT Announces $88 Million Public Offering of Common Stock
Jun 07, 01
07:03 ET	New England Journal Of Medicine Article on TKT's Non-Viral Gene Therapy System Demonstrates Promising Clinical Effects in Patients With Severe Hemophilia A
07:03 ET	Promising Gene Therapy Results May Lead to Future Cure of Hemophilia Complications
Jun 05, 01
16:28 ET	Journal of the American Medical Association Publishes Results of TKT's Replagal(TM) Enzyme Replacement Therapy Demonstrating Clinical Benefit in Patients with Fabry Disease
May 29, 01
08:50 ET	TKT Announces Issuance of Second U.S. Patent Covering Alpha-L-Iduronidase Enzyme for the Treatment of Hurler Syndrome (MPS I)
May 18, 01
08:31 ET	Pivotal Clinical Results of Replagal(TM) Presented at International Congress of Human Genetics
Apr 30, 01
16:30 ET	TKT Reports First Quarter 2001 Financial Results
Apr 11, 01
11:23 ET	High Court of Justice Issues Ruling in Erythropoietin Patent Litigation
Mar 28, 01
11:25 ET	TKT's Replagal(TM) Receives Recommendation for Approval in European Union
Mar 13, 01
08:29 ET	TKT Strengthens Intellectual Property Position for Rare Genetic Diseases With Issuance of Patent for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Feb 27, 01
08:31 ET	TKT Announces New Executive Appointment and Promotion
Feb 13, 01
08:32 ET	TKT Receives U.S. Patent for Gene Targeting Technology
Feb 08, 01
16:37 ET	TKT Reports Year-End 2000 financial results
Jan 19, 01
19:46 ET	U.S. District Court Issues Ruling In Erythropoietin Patent Litigation
Jan 03, 01
18:31 ET	TKT Receives FDA Complete Review Letter on Replagal(TM)
Jan 02, 01
08:30 ET	TKT Files IND to Begin Clinical Testing of Iduronate-2-Sulfatase for the Treatment of Hunter Syndrome
Dec 13, 00
16:36 ET	TKT Files Shelf Registration Statement and Adopts Shareholder Rights Plan
Dec 08, 00
08:29 ET	TKT Regains Rights to Second Gene-Activated(R) Protein From Aventis Pharma
Dec 04, 00
18:45 ET	TKT Reports Encouraging Results in First Human Investigation Of Hemophilia A Gene Therapy
Nov 28, 00
08:33 ET	TKT Announces Issuance of U.S. Patent Covering Iduronate 2-Sulfatase Enzyme For the Treatment of Hunter Syndrome (MPS II)
Nov 22, 00
08:29 ET	TKT Provides Update on Dynepo(TM) Regulatory Status in the United States
Nov 21, 00
08:32 ET	TKT Announces Issuance of U.S. Patent Covering Alpha-L-Iduronidase Enzyme for the Treatment of Hurler Syndrome (MPS I)
Oct 24, 00
09:38 ET	TKT Reports Third Quarter 2000 Financial Results
08:29 ET	TKT Reports Third Quarter 2000 Financial Results
Oct 06, 00
16:25 ET	TKT Breaks Ground for New Corporate Headquarters - First Long Distance Telephone Call Made from Site of New Headquarters -
Oct 05, 00
14:41 ET	Pivotal Clinical Results of Replagal(TM) Presented at American Society of Human Genetics Conference
Sep 19, 00
12:36 ET	TKT Files Complaint Seeking Declaratory Judgment Against Genzyme
Aug 03, 00
08:20 ET	Aventis Pharma Seeks Marketing Approval for Dynepo(TM) - Authorization Sought for Product Co-Developed With TKT -
Jul 27, 00
08:47 ET	TKT Reports Second Quarter 2000 Financial Results
Jul 25, 00
17:23 ET	TKT Announces Patent Infringement Suit by Genzyme Relating to Replagal(TM)
Jul 19, 00
15:59 ET	TKT Announces Acceptance of MAA in Europe for Replagal(TM) for the Treatment Of Fabry Disease
Jul 17, 00
09:36 ET	TKT Forms European Company to Market Niche Protein Products -TKT Europe-5S AB Receives Recommendation for European Orphan Drug Designation of Replagal(TM)-
Jun 16, 00
12:30 ET	TKT Submits Biologics License Application for Replagal(TM) to Treat Fabry Disease
Jun 12, 00
09:12 ET	TKT and Aventis Pharma Motion for Judgment of Non-Infringement Granted by U.S. District Court
May 30, 00
10:33 ET	TKT Receives U.S. Patent Covering Gene Targeting
May 22, 00
08:32 ET	TKT Announces Appointment of Michael Astrue as Senior Vice President, Administration and General Counsel
May 19, 00
08:45 ET	TKT Announces $100 Million Private Placement of Preferred Stock With Warburg Pincus
May 02, 00
08:18 ET	TKT Elects Walter Gilbert to Board of Directors
Apr 26, 00
15:39 ET	TKT and Aventis Pharma Provide Update on GA-EPO Patent Litigation
Apr 19, 00
08:32 ET	TKT Reports First Quarter 2000 Financial Results
Apr 11, 00
09:43 ET	TKT Awarded U.S. Patent for Erythropoietin Gene Therapy - Company Receives Two Additional Gene Therapy Patents -
Mar 09, 00
08:29 ET	Transkaryotic Therapies Awarded Transgenic Patent
Feb 10, 00
16:29 ET	TKT Reports Year-End 1999 Financial Results
Jan 11, 00
10:35 ET	TKT Announces Completion of Pivotal Phase III Renal Studies of Gene-Activated(TM) Erythropoietin
Dec 28, 99
08:29 ET	TKT Completes Phase II Study of Alpha-Galactosidase A for the Treatment of Fabry Disease
Dec 21, 99
11:01 ET	TKT Earns Milestone Following Submission of Investigational New Drug Application For Second Gene-Activated(TM) Protein
Nov 30, 99
10:31 ET	TKT Awarded Broad Gene Therapy Patent for the Delivery of Erythropoietin
Nov 17, 99
14:44 ET	Wayne P. Yetter Joins TKT Board of Directors
08:29 ET	Wayne P. Yetter Joins TKT Board of Directors
Nov 02, 99
11:10 ET	TKT Names Vice President, Quality and Announces Two Promotions
Oct 29, 99
08:05 ET	TKT Announces $132 Million Private Placement
Oct 20, 99
11:49 ET	TKT Expands Commercial Operations Group
11:46 ET	TKT Reports Third Quarter 1999 Financial Results
Oct 19, 99
11:51 ET	TKT Broadens Gene Activation Patent Portfolio
11:26 ET	TKT Broadens Gene Activation Patent Portfolio
Sep 22, 99
12:04 ET	TKT Updates Status of Erythropoietin Litigation
Jul 19, 99
12:02 ET	TKT Reports Second Quarter 1999 Financial Results
Jun 09, 99
12:00 ET	TKT AND HOECHST MARION ROUSSEL MOVE TO REOPEN GENE-ACTIVATED(TM) ERYTHROPOIETIN LITIGATION IN DISTRICT COURT -- Companies Also Request Acknowledgement of Non-Infringement in U.K. --
09:14 ET	TKT and Hoechst Marion Roussel Move To Reopen Gene-Activated(Tm) Erythropoietin Litigation In District Court
Apr 16, 99
11:57 ET	TKT Reports First Quarter 1999 Financial Results
Apr 13, 99
11:54 ET	TKT Appoints William H. Pursley Senior Vice President, Commercial Operations
Feb 09, 99
11:56 ET	TKT Reports Year End 1998 Financial Results
Jan 13, 99
10:33 ET	TKT and Sumitomo Form Collaboration to Commercialize Enzyme Replacement Therapy for Fabry Disease in Japan and Far East